 effect recombin human human hematopoiet progenitor precursor cell vivo dna-synthesi rate concentr bone marrow BM peripher blood PB progenitor cell patient recombin human part clinic phase i/ii studi recombin dose subcutan bolu inject day patient solid tumor hematopoiet function patient bone marrow failur myelodysplast syndrom treatment percentag BM erythroid bfu-e multilineag cfu-gemm progenitor patient preserv hematopoiet function dna-synthesi rate earli late granulocyt macrophag progenitor cell cfu-gm day cfu-gm day increas BM cellular myeloid ratio concentr marrow progenitor per cell basi unchang frequenc blast cell BM unchang mean level PB cfu-gm day cfu-gemm baselin valu day initi level end treatment peripher blood bfu-e major patient normal marrow day augment bfu-e cfu-gemm patient md PB bfu-e cfu-gemm total leukocyt neutrophil eosinophil count patient peak respons median day small increas reticulocyt elev hemoglobin hematocrit platelet count patient preserv marrow function induc multilineag respons vivo prolifer multipotenti lineage-restrict progenitor due effect progenitor cell